[go: up one dir, main page]

MX2017002948A - Métodos de tratamiento para la sarcoidosis pulmonar. - Google Patents

Métodos de tratamiento para la sarcoidosis pulmonar.

Info

Publication number
MX2017002948A
MX2017002948A MX2017002948A MX2017002948A MX2017002948A MX 2017002948 A MX2017002948 A MX 2017002948A MX 2017002948 A MX2017002948 A MX 2017002948A MX 2017002948 A MX2017002948 A MX 2017002948A MX 2017002948 A MX2017002948 A MX 2017002948A
Authority
MX
Mexico
Prior art keywords
pulmonary sarcoidosis
tretaing
mucolytic agents
dnase
mucolytic
Prior art date
Application number
MX2017002948A
Other languages
English (en)
Inventor
Burns Barry
Original Assignee
Gotham Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gotham Biopharmaceuticals Inc filed Critical Gotham Biopharmaceuticals Inc
Publication of MX2017002948A publication Critical patent/MX2017002948A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En el presente se describen métodos de tratamiento para la sarcoidosis pulmonar. Los pacientes que necesitan tratamiento para la sarcoidosis pulmonar reciben la administración de una cantidad terapéuticamente efectiva de un agente mucolítico tal como la DNasa I. En algunas formas de realización la DNasa I es una DNasa I recombinante humana tal como la dornasa alfa.
MX2017002948A 2014-09-08 2015-09-04 Métodos de tratamiento para la sarcoidosis pulmonar. MX2017002948A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462047361P 2014-09-08 2014-09-08
PCT/US2015/048606 WO2016040169A2 (en) 2014-09-08 2015-09-04 Methods of treating pulmonary sarcoidosis

Publications (1)

Publication Number Publication Date
MX2017002948A true MX2017002948A (es) 2017-08-15

Family

ID=54697634

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002948A MX2017002948A (es) 2014-09-08 2015-09-04 Métodos de tratamiento para la sarcoidosis pulmonar.

Country Status (11)

Country Link
US (2) US9402884B2 (es)
EP (1) EP3191090A2 (es)
JP (1) JP2017527618A (es)
KR (1) KR20170045750A (es)
CN (1) CN107249621A (es)
AU (1) AU2015315455A1 (es)
BR (1) BR112017004533A2 (es)
CA (1) CA2960622A1 (es)
IL (1) IL250980A0 (es)
MX (1) MX2017002948A (es)
WO (1) WO2016040169A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
IL317968A (en) 2017-08-18 2025-02-01 Neutrolis Inc Engineered deoxyribonuclease enzymes and their use in medicine
JP2022504400A (ja) 2018-10-08 2022-01-13 ニュートロリス インコーポレイテッド 製造及び治療のためのｄｎａｓｅ酵素の操作
US11058724B2 (en) 2018-10-08 2021-07-13 Neutrolis, Inc. Methods of using DNASE1-like 3 in therapy
US10988746B2 (en) 2018-10-08 2021-04-27 Neutrolis, Inc. Manufacturing and engineering of DNASE enzymes for therapy
US11352613B2 (en) 2019-02-04 2022-06-07 Neutrolis, Inc. Engineered human extracellular DNASE enzymes
KR20210137061A (ko) * 2019-02-22 2021-11-17 실라 세라퓨틱 인크. 흡입성 치료제

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348343B2 (en) * 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
EP1004302A3 (en) 1998-10-29 2003-06-04 Ajinomoto Co., Inc. Immunomodulator
JP2007230919A (ja) * 2006-03-01 2007-09-13 Ki Pharma Kk 美白剤
DE602008005459D1 (de) * 2007-08-03 2011-04-21 Ucb Pharma Sa Sulfanylderivate und ihre verwendung als synthetische zwischenprodukte
US8236786B2 (en) * 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
BRPI0917567A2 (pt) * 2008-08-07 2015-11-17 Pulmagen Therapeutics Inflammation Ltd tratamento de doença respiratória
GB201014391D0 (en) * 2010-08-27 2010-10-13 Biocopea Ltd Drug composition and its use in therapy
GB201111485D0 (en) * 2011-07-05 2011-08-17 Biocopea Ltd Drug composition and its use in therapy
GB201002224D0 (en) * 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment

Also Published As

Publication number Publication date
US20160067317A1 (en) 2016-03-10
AU2015315455A1 (en) 2017-04-27
US20170368150A1 (en) 2017-12-28
WO2016040169A3 (en) 2016-05-26
EP3191090A2 (en) 2017-07-19
CA2960622A1 (en) 2016-03-17
CN107249621A (zh) 2017-10-13
BR112017004533A2 (pt) 2018-05-08
KR20170045750A (ko) 2017-04-27
IL250980A0 (en) 2017-04-30
US9402884B2 (en) 2016-08-02
WO2016040169A2 (en) 2016-03-17
JP2017527618A (ja) 2017-09-21

Similar Documents

Publication Publication Date Title
MX2017002948A (es) Métodos de tratamiento para la sarcoidosis pulmonar.
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
PH12017502103A1 (en) Methods and kits for treating depression
MY192055A (en) Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation
MX385283B (es) Tratamiento de cáncer usando 2-desoxi-2-fluoro-l-fucosa en combinación con un inhibidor del punto de control.
IL273169A (en) A new combination of active substances for the treatment of advanced interstitial and lymphoid lung diseases
BR112017011900A2 (pt) tratamento de ataques com fosfatase alcalina recombinante
AR101740A1 (es) Terapia de combinación y composiciones
MY195038A (en) A Modified Release Composition of Orlistat and Acarbose for the Treatment of Obesity and Related Metabolic Disorders
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
PH12017500392A1 (en) Medical treatments based on anamorelin
PH12018502161A1 (en) Methods of treatment for cholestatic and fibrotic diseases
MX2019015212A (es) Compuestos para el tratamiento del sarcoma.
MX375924B (es) Moduladores de proteinas del choque termico 70 (hsp70) y metodos para fabricar y usar el mismo.
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica
ZA201906153B (en) Pharmaceutical compositions for combination therapy
EA201692196A1 (ru) Применение 1,3-пропандисульфоновой кислоты или ее фармацевтически приемлемых солей для лечения саркоидоза
BR112015028334A2 (pt) agente e método para o tratamento de herpes
EA201591184A1 (ru) Применение пидотимода для лечения атопического дерматита
EA201991866A1 (ru) Комбинированная терапия
UA106471U (uk) Засіб для лікування дерматологічних захворювань
MX2017011838A (es) Composiciones y metodos para tratar carcinoma hepatocelular.
UA88138U (ru) Лекарственное средство в форме перорального раствора для лечения и профилактики ишемии тканей организма
IN2014DE00822A (es)
RU2014123959A (ru) Способ лечения синдрома болевой дисфункции височно-нижнечелюстного сустава при остеопорозе